{"name":"Lantern Pharma","slug":"lantern","ticker":"LTRN","exchange":"NASDAQ","domain":"lanternpharma.com","description":"Lantern Pharma is a biopharmaceutical company leveraging AI and machine learning to accelerate the discovery and development of oncology treatments. The company focuses on developing novel therapeutics for various types of cancer. With a strong pipeline and strategic partnerships, Lantern Pharma is well-positioned to make a significant impact in the oncology market.","hq":"Dallas, TX","founded":0,"employees":"","ceo":"Panna Sharma","sector":"Oncology / AI Drug Development","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$65M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":11514123,"netIncome":-17119438,"cash":4422838,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"XPO1 inhibitor patent cliff ($0.00 at risk)","drug":"XPO1 inhibitor","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Lantern Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Lantern Pharma reported its financial results for the fourth quarter and full year 2023, highlighting progress in its pipeline and partnerships.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Lantern Pharma Announces Collaboration with Leading Cancer Research Institute","summary":"Lantern Pharma partnered with a leading cancer research institute to advance its oncology pipeline.","drugName":"","sentiment":"positive"},{"date":"2023-08-15","type":"trial","headline":"Lantern Pharma Announces Positive Interim Results from Phase 2 Clinical Trial","summary":"Lantern Pharma reported positive interim results from a Phase 2 clinical trial for its lead oncology candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQZnlFRUNkYXlISzV0YndYWWhseVI5WlBwTnpxMnEtZE14elJoVDhMY0R1cmpqb0t5cFV2ZnRteVp5MDRaUkVMQTdkRWdyM2VJUlJNdjdBMkhlYktlMkFRYnlLWkZfaVhlWVFfUjA2LWxyQW8zeEFObGpNajBJWkMtUDNERGxXdEJweG90Mm5ZMHp0UHhjU2lLOUs4MmRGSDdybUtnNFdnT1F3WkFQNC1rSFB0U3RhTkRRNF9aRTNkdk55UDQ?oc=5","date":"2026-04-03","type":"pipeline","source":"Stock Titan","summary":"Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake - Stock Titan","headline":"Lantern Pharma (NASDAQ: LTRN) insider holds 570,000 shares, 5.1% stake","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQY2Q3aG5famFjeWpPemFlb1VtNjIzTWtkOHQ0OXB0dk50N3BDZmx0Vl9LNWVoMzR5c0VLVXpfdGZWWEY0QkZFMWc5MDVxRTI1eEhnbEJBLWpCWG5TeVFIVDlfVElvS0hUaGhPYm9YN0pxLVBCdlh4ODItNjBKRVhpTTdpRXZhN251ZGhUTWJCMWllTEhVaEZfaE5TT2Z4MEZBSTlLNi0xQkprZlhQUXc0cC1HbEJwT0xKTjhVemduekV0OFJzUkJfX2VwNTJYTTM2c0EzUnNSSXVWVThGVGFyU1k0cTVBVTA?oc=5","date":"2026-04-03","type":"earnings","source":"GuruFocus","summary":"Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra - GuruFocus","headline":"Lantern Pharma Inc (LTRN) Q4 2025 Earnings Call Highlights: Stra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNZlVreXVMN185bFFPQUxzelVnUWQzdG1BTmI2MXVwWTBxMWl6T0pBS1luZnNVd0I3MlF5bVhSekEzZ1dIM0tVdUlpZE9ueU1FOUczaThodHJVUDVvNXNldUdMakZOamVSbk1FWlRzR3ZLWnhXdTNnSHVLeGtKYUNfSGdYNW1leVQ3c3VkWkh1ZU9BTzRfaHZXdWN3TzRfek1iRFpnV3lUZ1pmQQ?oc=5","date":"2026-04-02","type":"pipeline","source":"TipRanks","summary":"Lantern Pharma to host live demonstration of withZeta.ai - TipRanks","headline":"Lantern Pharma to host live demonstration of withZeta.ai","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxOS05tYmFzUFExcVljNElRN1F3TGg4Mnd1QXBzeEZ3U3NOZFNqWUdHZXhnbXpFTmozT2M3UzRHLVN1eUh2WW9uOEdmUFNPSHV2SWtWZUpvRmgtMUxHZjc1YnZsRVYteFV6VGp3VlJfbHlzSHc1QWYxNFZ2X0ZrakZVc2h0OXZxUEVwM1dWZWwtVUxIeXU3?oc=5","date":"2026-04-02","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8:","headline":"Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPLVgwaXN0clF6RFBDVDduOGpnbk9wcG9nMGFta1B0VGxRalJ5dFpzeUJVLVBBZFhWRnE4QUNtYUNXcElsTTZKUEx6Y2NHRl9CWTlCcEttS0pfUnNpdWZaeEhpak51Z3hVYzB2cjVyU3o2RVEzWHlXV2JXcHJqREtXUkpCYXM5Wlh6ckdkd1FEeTlQdFVuMVlrelVQZk9ISTloOENEYUdfLURaTm1pWlYweERuWmxQeGplTWFDLQ?oc=5","date":"2026-04-02","type":"pipeline","source":"GuruFocus","summary":"Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R - GuruFocus","headline":"Lantern Pharma (LTRN) to Showcase AI Innovation in Rare Cancer R","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQY3ZSUlItdzVHeGhjZlA0cUxkMldlM1g0WEpZdmxGNmpmcVVteVJpc1B0SzZfRElreV9ucGQ0bGpRZFRDVGppaG52UUwzZUJuSmJkM3FNZTNjYlFYQnVHRi1LQ0M0NzMwc08yak9ycHI3TFVWQmNZdnJHOTl1blRPbTM1UTFnZGZLblBfU21pajdqSlRzMjZJOV9XTVdwSS1GNGVucA?oc=5","date":"2026-03-30","type":"earnings","source":"Seeking Alpha","summary":"Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-03-30 - Seeking Alpha","headline":"Lantern Pharma Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:LTRN) 2026-03-30","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQdVBia3JOSDhJbkVUdUhkYnJkMm9YNDJfcFRTRjhSeEtZZXhhYVdXODVmVm05MjVhby10TUViNW9sQmZQNlVSaTVjMVU2UEtMSUV1UnJUWXhTT2JrR3IzQl9GaFU1R3hzendkbXFHcTV5cDZPQ3d3a2lwU25Ndk5lOWVmM3pTYjQyZFJYcVR1X1Z0MDd2M054RVdyS1A0SnRMVUZBYUE0d19pMS1lRVhmZGd1RnFtNGdjZUlFa0NrMGl4bE15UXl0X0pGVmMzRmNOYk5IYnozM1FxakxaSzBKNF9zOGQtOWwxbUpRNHEwSWR0bGZCUzVMaUNUZ2NKUVZQdzVtZUR6WVBJdDdYdlNFRkxoZHNhNTk4dlltMmNXZTg1dzYwY2dLVVJMbW5QSjkzVTg0T25RbWZBODRDcHhUMUlKMkp6eDFa?oc=5","date":"2026-03-30","type":"pipeline","source":"MSN","summary":"Lantern Pharma (LTRN) price target increased by 25.00% to 25.50 - MSN","headline":"Lantern Pharma (LTRN) price target increased by 25.00% to 25.50","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOZ1pXaWE2TXllSl8yWVF3bjE5cklhVkNiZk5qWFB3dGtVeWJ6dVRIYnVvaFAwN3BuZERnTUZuWktNaXdqZlpoN081UmZPLXczRWZuRktlT2RTT1dCT2JGanoySTIxVjJXTVdTTV92Mm5MS250bnFDSVUyR2pmUVd0Wm5rSTR1Y2xsM2lsenVLLTBqQzVabklNWHJEd2poNnNCRXVpLTNqd2I?oc=5","date":"2026-03-30","type":"pipeline","source":"Stock Titan","summary":"Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk - Stock Titan","headline":"Lantern Pharma (NASDAQ: LTRN) outlines AI-driven cancer pipeline and going concern risk","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNUU9QSW5BWURISjlPTmt3dHhUd1NaNFZkcXJ2N093ay1XQWtVbjlVd3A2eF94SFlCNS1CSHF2TWVia3gyLU01amNxVGQtaVYyZUxNYkpTZjZ2eFpsNVhjZ2MzME5jZDlSUkdxRS1oREYzVF9MV2tLZnBIbXNxOC0wN2taM25CQW5KWmI1Qkd2TWhnXzcyNzJmQ18yUFFOVTFCTURSWHlRZHhBWVRNVy1IVXE3blBWWVYwZUxXTjhfSnFLSVlSR3ZxX2RyOUxObUlhM0NZRVJraWV3d0JvYmVrQi10b2pueXJGNDlEVTQ3UWN2MlNBeWdQdEZzXy1yZzl4c0l2OEZBRkRodw?oc=5","date":"2026-03-27","type":"pipeline","source":"Business Wire","summary":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Business Wire","headline":"Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Repo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwJBVV95cUxOMmhTS2RvSm1NWkhtYzlodHRSWlR5eE15ZVF1N1NiMjVGUzVyZzQ0Nm5RM0NpSlZsT3ZrMFJxcEg5ZzRnU1dWSXlkZ0RiLVVtMHl4dXZrTk9DdGstVl9KcWdXY0VLVXF5X3dZOHpwM2thc1JndWJEV3FvaTlQQU9CR3MwTHJmVy1mUmdCRFFockQ3OHlySXVJeUNXZXlEV2JpUUhWNFFvVWVwOVNZSjFVYVdXNnZkYWJkcFJycnJLQWs3YkVUZEJaVDVQUUtaRjhOaGFHY1pjZXR6d0ZVd1JJMWhTazJGdFFsNjUyQTBmUk8tMlhuejh6SGlMMERJUUFIdWQ3THlmNk5Rb3c?oc=5","date":"2026-03-23","type":"earnings","source":"Business Wire","summary":"Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET - Business Wire","headline":"Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOeGVURmJYckg4NF9UenQ3VjFBbk9Hak1jMEktcEk1WW42cF9BRkpnaXFmYVpUN0tldWl6YmpUV0Vpd0FkNmxZX295cHVZaExJc1VzalFwZ0hSYzU3ai1LaF9Yc1NrWlBlSENjTFNwN2ZBQVBCSW9SQmlsX2ZaWDM3M1VjWnhILWhuZDRN?oc=5","date":"2026-02-12","type":"pipeline","source":"Yahoo Finance","summary":"Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Yahoo Finance","headline":"Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition","sentiment":"neutral"},{"date":"2026-01-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-21","type":"pipeline","source":"simplywall.st","summary":"Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely - simplywall.st","headline":"Here's Why Lantern Pharma (NASDAQ:LTRN) Must Use Its Cash Wisely","sentiment":"neutral"}],"patents":[{"drugName":"XPO1 inhibitor","drugSlug":"xpo1-inhibitor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Clovis Oncology","Agenus","Nektar Therapeutics"],"therapeuticFocus":["Oncology"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":11514123,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-17119438,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":4422838,"cashHistory":[],"totalAssets":11035811,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}